# A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

Clinical trial · Janssen Research & Development, LLC

- Archive id: nct:NCT02782104
- Published: 2016-05-25
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT02782104
- Source URL: https://clinicaltrials.gov/study/NCT02782104
- Provenance: clinicaltrials

## Abstract

The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: SUSTAIN-3
- status: COMPLETED
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 1148
- sponsor: Janssen Research & Development, LLC
- conditions: Depressive Disorder, Treatment-Resistant
- interventions: DRUG: Esketamine Nasal Spray
- start date: 2016-06-09
- start date type: ACTUAL
- primary completion date: 2022-12-30
- has results: true
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Novel Psychiatric Therapeutics](https://space-kitty.com/topics/psychiatric-therapeutics)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.